Latest Nasdaq News

BPH Energy’s latest quarter puts its portfolio risks in sharp relief: Advent is appealing the PEP11 ruling while another subsidiary remains in voluntary administration. BPH ended September with $1.127 million in cash, but deployed $972,000 in loans to investees during the quarter.

NOVONIX has replaced a binding PowerCo supply agreement covering at least 32,000 tonnes of synthetic graphite with a framework that leaves volume and price unresolved. A new offtake deal will only be negotiated after customer qualification and further certification.

European Lithium has secured a date for the Supreme Court of Western Australia to consider approval of its proposed acquisition by NASDAQ-listed Critical Metals Corp. Several transaction conditions have been satisfied, waived or appear on track, but securityholder votes and court approval remain outstanding.

Mesoblast has reported a sharp first-quarter commercial improvement, with Ryoncil revenue rising 44% and net operating cash spend falling 85% year on year. The company ended September with US$99 million in cash, although the figures remain preliminary.

Kelly Partners Group Holdings has secured conditional ASX approval to delist, clearing a regulatory milestone in its proposed move to Nasdaq. The plan still depends on shareholder approval and the US listing process, with no effective delisting date set.

Cleo Diagnostics has moved its pre-surgical ovarian cancer test into formal Analytical Validation, a key regulatory step before its planned FDA 510(k) submission in the first half of 2027. The three-batch program is expected to take about three months, but no validation results have yet been reported.

Venari Minerals has exercised its option to acquire a Nevada property and private water entitlement near its Red Mountain Lithium Project for total consideration of US$400,000. The deal addresses a stated development constraint, although completion and the project’s broader economics remain ahead.

Elevra Lithium has signed a binding supply agreement with LG Energy Solution for 240,000 dry metric tonnes of spodumene concentrate from Québec over the stated three-year term. The market-linked deal gives North American Lithium a committed battery-sector customer while preserving exposure to lithium prices.

High-Tech Metals has installed a new leadership team and arranged an 11.9% share crossing as it shifts focus from exploration to production at its Western Australian gold projects. The strategy is backed by approximately A$9 million in cash, but still depends on studies, approvals and shareholder decisions.

Radiopharm says the FDA has provided a clear framework for the pivotal development of RAD101, its investigational brain metastases imaging agent. The company is preparing for Phase 3 while awaiting formal meeting minutes that could still refine the trial design and regulatory requirements.

Sunrise Energy Metals has signed a scheme deed to move its parent company from Australia to Delaware and make Nasdaq its primary listing, while retaining ASX exposure through CDIs. The proposed one-for-one exchange remains subject to shareholder, court, regulatory and listing approvals.

Chilwa Minerals has lodged a prospectus supporting a fully underwritten US$3.5 million Nasdaq IPO, with most of the proceeds earmarked for exploration at its Chilwa Critical Minerals Project. The raising would strengthen its cash position, but the prospectus also flags material going-concern uncertainty and further funding needs.